Cardiovascular Revascularization Medicine

including Molecular Interventions


Cardiovascular Revascularization Medicine (CRM) is an international, English-language, multidisciplinary, peer-reviewed journal that publishes original laboratory and clinical investigations related to revascularization therapies in cardiovascular medicine. CRM publishes 12 regular print issues and a supplemental issue each year.

The journal is indexed on Index Medicus and MEDLINE®/PubMed®.

The journal's location in Washington, DC, gives it an advantage in reporting on regulatory issues as they pertain to interventional cardiology and structural heart disease. The journal is read by cardiologists, interventional cardiologists, structural heart interventionalists, vascular physicians, healthcare regulators, industry, fellows in training, and innovators around the globe.

CRM is also the official journal of the Cardiovascular Research Technologies (CRT) meeting, a premier event that brings together about 3,000 interventional cardiologists annually to discuss cutting-edge research and innovations. Attendees are encouraged to submit papers based on abstracts, interesting cases, late-breaking trials, and innovations presented at the meeting that impact interventional cardiologists' practice. The journal structures its content to reflect topics based on each track of the CRT meeting: Complex Coronary, Valve and Structural, Endovascular, Imaging and Physiology, Atherosclerosis, Cardiogenic Shock, Technology and Innovation, Regulatory and Healthcare Policy, and Innovations.

CRM publishes articles related to preclinical and clinical work, including pharmacological interventions, and restenosis management; and treatment, including experiments conducted in human subjects, laboratory animals, and in vitro. Specific areas of interest include percutaneous angioplasty in coronary and peripheral arteries, intervention in structural heart disease, cardiovascular surgery, congenital heart disease, coronary heart disease, genetics and translational science, health services and outcomes research, invasive imaging, regulatory and health policy, technology and innovation, and vascular medicine.

The journal's nearest competitors are JACC: Cardiovascular Interventions, Circulation: Cardiovascular Interventions, and EuroIntervention.

CRM will consider all articles describing clinical trials and translational research (i.e., those that unite the clinic with the laboratory). The journal publishes original articles, research letters, reviews, editorials, and special features. Original articles that address any aspect of cardiovascular revascularization or structural intervention are invited. Letters to the editor, trial design papers, and interesting images are encouraged. The journal's peer-review process is single-blind.